PROTALIX BIOTHER

PLX AMEX
0.3870
-0.0128
-3.20%
Closed 16:00 07/18 EDT
Open
0.3965
Prev Close
0.3998
High
0.4000
Low
0.3851
Volume
391.38K
Avg Vol (3M)
256.14K
52 Week High
0.8300
52 Week Low
0.2700
% Turnover
0.26%
Market Cap
57.42M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers PROTALIX BIOTHER PLX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.
MORE >

Recently

Name
Price
%Change